All In Biotech

Drug Trial Radar · NCT05903794

A Study of EXG102-031 in Patients With wAMD (Everest)

An Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration.

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 24, 2023

Primary completion

Feb 16, 2026

Study completion Feb 16, 2026

Sponsor

Lead sponsor
Exegenesis BioIndustry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD.

Conditions

  • Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Interventions

  • EXG102-031Biological

    EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of safety and tolerabilityTime frame: Throughout 52 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sierra Eye Associates

    Reno, Nevada

  • Erie Retina Research

    Erie, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.